Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]

This drug was developed by Bristol-Myers Squibb.

References

  1. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol, American Medical Association.
Allikas: https://en.wikipedia.org/wiki/Lulizumab_pegol
No tags for this post.